---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-009499"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:12:18.120564+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bio-Path Q1 net loss $5.3M ($0.66/share); cash burns to $6.7M; clinical milestones Q2/3

## Summary
- Net loss $5.3M ($0.66/share) vs $3.4M ($0.47) Q1 2022; R&D spend doubled to $4.0M.
- Cash $6.7M at Mar 31, down from $10.4M Dec 31; net cash used in ops $3.7M.
- BP1001-A solid tumor trial initial cohort completion/data readout expected mid-2023.
- BP1002 relapsed/refractory AML cohort readout expected mid-2023.
- Prexigebersen Phase 2 AML: two cohorts exceeded min efficacy for expansion; interim analyses start Q2 2023.

## SEC filing metadata
- accession: 0001558370-23-009499
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837023009499/0001558370-23-009499-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837023009499/bpth-20230512x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-009499
- JSON: https://secwatch.observer/filing/0001558370-23-009499.json
- Plain text: https://secwatch.observer/filing/0001558370-23-009499.txt

## Key facts
- Earnings Releases
  BIO-PATH HOLDINGS, INC. reported first quarter ended March 31, 2022 results: net income a net loss of $3.4 million, or $0.47 per share.
  - Period: first quarter ended March 31, 2022
  - Net income: a net loss of $3.4 million, or $0.47 per share
  - Result: reported results
  source text: The Company reported a net loss of $5.3 million, or $0.66 per share, for the three months ended March 31, 2023, compared to a net loss of $3.4 million, or $0.47 per share, for the three months ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133818/000155837023009499/0001558370-23-009499-index.htm
- Earnings Releases
  BIO-PATH HOLDINGS, INC. reported first quarter ended March 31, 2023 results: net income a net loss of $5.3 million, or $0.66 per share.
  - Period: first quarter ended March 31, 2023
  - Net income: a net loss of $5.3 million, or $0.66 per share
  - Result: reported results
  source text: The Company reported a net loss of $5.3 million, or $0.66 per share, for the three months ended March 31, 2023, compared to a net loss of $3.4 million, or $0.47 per share, for the three months ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133818/000155837023009499/0001558370-23-009499-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.